Sitagliptin and lobeglitazon justification must be reasonable, the CDSCO panel instructs Synokem Pharma.

Published Date: 22 May 2023

New Delhi: In keeping with the bioequivalence (BE) discussion and phase III clinical trial protocol proposed by the pharmaceutical company Synokem.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Examines Office-Based Transperineal Prostate Biopsies Methodology.

2.

A global study demonstrates that screening for lung cancer significantly raises the long-term survival rate.

3.

Is a $2,000 Whole-Body MRI Worth It?

4.

Surgery may not be necessary to treat invasive breast cancer

5.

Limited Benefit from New Drugs; Significant Increase in Drug Prices; AI Boost for Mammo Results.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot